We further show using siRNA that GSTO1 is an important survival factor for cancer cells
Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity
But there is some evidence that GLP-1 agonists like semaglutide may decrease cancer risk beyond just their ability to help people lose weight
Bloating that happens when you try new foods or eat larger portions than your body can manage points to a mismatch between your habits and how your body processes food
Biohackers and wellness enthusiasts have long been known to use fermented foods to boost gut diversity, but the shift towards whole health wellness has invited new consumers into the fold
At Arrowhead Medical and Wellness Center in Peoria, we craft individualized weight loss plans using FDA-approved medications like Semaglutide, Tirzepatide, and Phentermine, paired with expert guidance to ensure success